Telix Group inks deal with ININ to boost prostate imaging technology
Category: #health  By Pankaj Singh  Date: 2019-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Group inks deal with ININ to boost prostate imaging technology

Telix Pharmaceuticals Limited, through its wholly-owned subsidiary Advanced Nuclear Medicine Ingredients SA (ANMI), has recently announced that it has entered into an agreement with Mexico’s Instituto Nacional de Investigaciones Nucleares (ININ) and completed the in-licensing of ININ’s 99mtechnetium-EDDA/HYNIC-Lys (NaI)-Urea-Glu (99mTc-iPSMA). Apparently, the product is an innovative clinical-stage radiopharmaceutical for prostate cancer imaging.

According to Telix, Single Photon Emission Computed Tomography, termed as SPECT, is widely deployed nuclear medicine imaging procedure, particularly for managing cancer, being an alternative to the Positron Emission Tomography or PET approach already being developed by ANMI. SPECT, even though similar to PET with regards to radioactive trace usage and gamma ray detection, is the dominant nuclear imaging modality in cancer management due to less availability of PET/CT worldwide.

Sources close to the matter informed that the team of ININ and its partners have been able to clinically evaluate 99mTc-iPSMA with SPECT/CT, the results of which show highly sensitive detection of lesions in prostate cancer. There is considerable commercial and clinical potential of the product for evaluating both primary disease and metastases in regions where extensive PET infrastructure is not present.

Reportedly, 99mTc-iPSMA has strong international patent protection in several commercial markets. 99mTc-iPSMA has been developed as result of world-class research performed by innovative ININ research group from the National Laboratory on Research and Development of Radiopharmaceuticals (LANIDER), sources mentioned. The group has substantial experience in the nuclear medicine field. 

Through scientific partnerships with the National Laboratories of the National Council of Science and Technology (CONACyT) and Mexican National Institute of Cancerology (INCan), LANIDER group maintains numerous international and national collaborations.

For the record, Telix is headquartered in Melbourne and has operations internationally in the U.S., Japan and EU. Telix’s license agreement with ININ represents a worldwide agreement and also includes a partnership for manufacturing the product.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Walgreens and Kroger to form a new group purchasing venture
Walgreens and Kroger to form a new group purchasing venture
By Pankaj Singh

Walgreens, a renowned U.S. based pharmacy-led health, beauty and well-being company, and Kroger, an American retail company, reportedly announced that they would be expanding their existing relationship to create a new...

GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
By Pankaj Singh

 

  • The alliance is aimed at personalizing regenerative tissue manufacturing processes
  • Vascularized printed cells are set to pave the way for more complex biolog...

Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
By Pankaj Singh

Hummingbird Bioscience, an advanced biotherapeutics company, recently announced it has raised USD 19 million in a Series B funding round. Apparently, the financing round was co-led by GNTech Venture Capital and Mirae A...